GPX4 and myelodysplastic syndrome: In support of the role of this pathway in MDS, treatment of the MDS cell line SKM-1 and two myeloid leukemia cell lines (KG-1 and K562) with the ferroptosis inducer erastin was demonstrated to induce ferroptosis by depleting GSH and reducing GPX4 activity.